2025年青光眼治疗药物行业词条报告

Investment Rating - The report provides a positive outlook on the glaucoma treatment drug industry, indicating a stable growth trajectory with a compound annual growth rate (CAGR) of 7.49% from 2020 to 2024 and an expected CAGR of 6.47% from 2025 to 2030 [31][34]. Core Insights - Glaucoma is the leading cause of irreversible blindness globally, necessitating early detection and effective treatment, primarily through medication [4]. - The market for glaucoma treatment drugs is driven by an expanding patient base, improved insurance coverage, and accelerated domestic drug production [4][8]. - The industry is witnessing a shift towards domestic drug substitution, innovative drug development, and the integration of AI diagnostics [4][10]. Market Overview - The market size for glaucoma treatment drugs is projected to grow from 11.318 billion RMB in 2020 to 15.111 billion RMB in 2024, and further to 16.255 billion RMB in 2025, reaching 22.237 billion RMB by 2030 [31][34]. - The increase in glaucoma patients is significantly correlated with aging populations and increased screen time, leading to a younger demographic of patients [8][32]. Industry Characteristics - The treatment of glaucoma requires lifelong medication, resulting in stable market demand [9]. - The market has historically been dominated by imported brands, but local companies are increasingly capturing market share through competitive pricing and effective product offerings [10][18]. Development History - The industry has evolved from a nascent stage in the mid-19th century to a high-growth phase since the 1990s, with significant advancements in drug formulations and treatment methodologies [11][14]. Industry Chain Analysis - The industry chain consists of upstream raw material suppliers, midstream drug manufacturers, and downstream sales channels, with active pharmaceutical ingredients (APIs) being critical to production [16][17]. - The production of glaucoma drugs is characterized by high technical barriers and stringent quality standards, particularly for active ingredients [22][23]. Competitive Landscape - The competitive landscape is divided into three tiers, with leading companies like Shenyang Xingqi and Zhaoke occupying the top tier, followed by firms like Chengdu Kanghong and Lunan Better in the second tier, and smaller companies in the third tier [39][42]. - The market is experiencing a shift towards domestic innovation and high-end foreign formulations, with companies focusing on integrating new mechanisms and delivery systems [43][44]. Sales Channels - The sales of glaucoma drugs are primarily through hospital channels, which account for over 60% of the market, but online sales are rapidly growing, with significant year-on-year increases [28][30].